Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
RBGPF
0.0000
Zürcher Nachrichten - Novo Nordisk to slash prices of weightloss drugs in US
EUR
-
AED 4.133853
AFN 73.165428
ALL 92.126574
AMD 412.499777
ANG 2.015275
AOA 1033.321586
ARS 1716.426055
AUD 1.622495
AWG 2.02612
AZN 1.913917
BAM 1.959582
BBD 2.279068
BDT 139.128514
BGN 1.894919
BHD 0.426627
BIF 3396.956026
BMD 1.125622
BND 1.448896
BOB 13.629304
BRL 5.883288
BSD 1.131569
BTN 109.056445
BWP 16.007681
BYN 3.408633
BYR 22062.199401
BZD 2.275762
CAD 1.599459
CDF 2600.188108
CHF 0.931408
CLF 0.027984
CLP 1104.955675
CNY 7.546845
CNH 7.546949
COP 3736.233468
CRC 517.002393
CUC 1.125622
CUP 27.15705
CVE 110.733152
CZK 24.4575
DJF 201.496197
DKK 7.47518
DOP 67.611088
DZD 150.436019
EGP 58.880296
ERN 16.884336
ETB 181.224937
FJD 2.534111
FKP 0.853148
GBP 0.851832
GEL 2.920976
GGP 0.853148
GHS 13.256585
GIP 0.853148
GMD 82.797982
GNF 9954.388548
GTQ 8.644761
GYD 236.696818
HKD 8.83232
HNL 30.200793
HRK 7.537618
HTG 148.095821
HUF 368.865373
IDR 20138.510688
ILS 3.458565
IMP 0.853148
INR 108.290169
IQD 1482.341121
IRR 1965943.452561
ISK 136.999508
JEP 0.853148
JMD 178.225553
JOD 0.79808
JPY 177.456061
KES 146.004427
KGS 98.432333
KHR 4564.399327
KMF 493.02265
KPW 1013.060534
KRW 1520.243451
KWD 0.347659
KYD 0.943007
KZT 501.401008
LAK 25275.851325
LBP 100799.487869
LKR 373.946723
LRD 192.875293
LSL 18.792252
LTL 3.32367
LVL 0.680877
LYD 7.220911
MAD 11.035498
MDL 20.147616
MGA 4985.381985
MKD 61.694068
MMK 2363.670367
MNT 4050.403333
MOP 9.14613
MRU 45.109355
MUR 54.199002
MVR 17.391026
MWK 1955.205858
MXN 20.553021
MYR 4.597158
MZN 71.938848
NAD 18.741621
NGN 1495.017815
NIO 41.270936
NOK 10.823451
NPR 174.490311
NZD 2.003338
OMR 0.432804
PAB 1.131584
PEN 3.900848
PGK 5.008457
PHP 70.463659
PKR 311.85304
PLN 4.374276
PYG 6593.637662
QAR 4.102866
RON 5.342425
RSD 117.529594
RUB 93.844635
RWF 1669.737378
SAR 4.237066
SBD 9.077978
SCR 15.710406
SDG 677.068866
SEK 11.282862
SGD 1.439587
SHP 0.852615
SLE 27.687448
SLL 23603.730164
SOS 646.653768
SRD 42.405007
STD 23298.111438
STN 24.932537
SVC 9.900977
SYP 14635.34297
SZL 18.733906
THB 37.791084
TJS 10.421706
TMT 3.950935
TND 3.364223
TOP 2.710228
TRY 55.31601
TTD 7.676714
TWD 35.894967
TZS 2966.018463
UAH 50.809784
UGX 4492.670723
USD 1.125622
UYU 45.548312
UZS 13304.857024
VES 974.201464
VND 29260.554766
VUV 135.169589
WST 3.130211
XAF 655.957
XAG 0.018331
XAU 0.000268446037
XCD 3.042051
XCG 2.039309
XDR 0.795873
XOF 655.957
XPF 119.331742
YER 266.069002
ZAR 18.762077
ZMK 10131.967744
ZMW 22.251649
ZWL 362.449959
SSP 6430.221514
MXV 2.325538
- Eala-conqueror Wang wins Asian Games tennis gold and Olympic berth
- Tom Kim leads Asian Games golf in chase to avoid military service
- 'Kinda cool' Raygun made breakdancing famous, Asian Games B-girls say
- Asian stocks hit as oil spike fans rate hike bets, eyes on US jobs
- Taiwan gender-row boxer Lin Yu-ting wins 'monumental' Asian Games gold
- 'We're losing our scientists': west Africa's STEM struggle
- Taiwan receives its first US-made F-16V fighter jets
- World powers gather in Pacific to chart climate battle
- Lula, Bolsonaro trade scandal fire in final scramble for votes
- Return of swarming moth spectacle has Australia in a flutter
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
F.E.Ackermann--NZN
